Compare Davita Inc (DVA) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Verisign, Inc. — how do they compare? Davita Inc trades at $228.71 (market cap $14.92B), while Verisign, Inc. trades at $267.65 (market cap $24.47B). The key difference: Verisign, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.21% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | VRSN | |
|---|---|---|
Market Cap | $14.92B | $24.47B |
Sector | Health | Technology |
52-Week High | $235.71 | $310.00 |
52-Week Low | $103.87 | $211.49 |
Enterprise Value | $27.47B | $25.70B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
VeriSign (VRSN) trades at $270.31, up 0.07% with a bullish technical outlook. The stock shows strong fundamentals with 2025 revenue of $1.66B, net income of $825.7M, and exceptional 49.96% net margin. Recent Q1 2026 earnings beat expectations at $2.34 EPS. Analyst consensus is bullish with 57% buy ratings and $327.67 price target, representing 21% upside potential. The company maintains its monopoly position in .com/.net domain registry with predictable revenue growth.
VRSN presents a compelling investment case with stable cash flows and dominant market position, though trading at premium valuations (P/E 29.87). Key risks include contract renewals, AI disruption potential, and high debt levels. The upcoming Q2 2026 earnings report on July 23 will be critical for validating growth trajectory. Current levels offer attractive entry for long-term investors seeking defensive tech exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
